Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $136.6 million.

  • Haemonetics' Cost of Revenue fell 1188.04% to $136.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $535.9 million, marking a year-over-year decrease of 1649.52%. This contributed to the annual value of $611.9 million for FY2025, which is 91.35% down from last year.
  • Haemonetics' Cost of Revenue amounted to $136.6 million in Q4 2025, which was down 1188.04% from $132.6 million recorded in Q3 2025.
  • Over the past 5 years, Haemonetics' Cost of Revenue peaked at $167.4 million during Q1 2024, and registered a low of $117.4 million during Q4 2021.
  • In the last 5 years, Haemonetics' Cost of Revenue had a median value of $141.4 million in 2021 and averaged $140.6 million.
  • Per our database at Business Quant, Haemonetics' Cost of Revenue surged by 2094.82% in 2022 and then plummeted by 1990.6% in 2025.
  • Haemonetics' Cost of Revenue (Quarter) stood at $117.4 million in 2021, then grew by 24.91% to $146.6 million in 2022, then increased by 8.04% to $158.4 million in 2023, then decreased by 2.14% to $155.0 million in 2024, then decreased by 11.88% to $136.6 million in 2025.
  • Its Cost of Revenue stands at $136.6 million for Q4 2025, versus $132.6 million for Q3 2025 and $129.2 million for Q2 2025.